Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics

PathAI’s best-in-class Image Management System (IMS) with advanced AI analysis and workflow capabilities will complement Roche's digital pathology portfolio to drive laboratory efficiencyCombining...
April 30, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026

New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing...
April 23, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad-hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von +6% zu konstanten Wechselkursen im ersten Quartal 2026; -5% in CHF aufgrund der deutlichen Aufwertung des Schweizer Frankens

Konzernverkäufe stiegen in den ersten drei Monaten um +6% zu konstanten Wechselkursen (CER1; in CHF ausgewiesen -5% und auf USD-Basis2 +9%) aufgrund hoher Nachfrage nach innovativen Medikamenten und...
April 23, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc

Group sales were +6% at constant exchange rates (CER)1, -5% when reported in CHF and +9% in USD2, in the first three months, driven by high demand for our innovative medicines and...
April 21, 2026 19:15 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple...
April 21, 2026 11:45 ET | Source: F. Hoffmann-La Roche Ltd

Roche’s ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD

Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous...
April 21, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus

Filing acceptance based on phase III ALLEGORY data for Gazyva/Gazyvaro showing a significant reduction in disease activity compared with placebo in people with systemic lupus erythematosus (SLE)If...
April 13, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche receives CE mark for new Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis.1This minimally invasive blood test enables...
March 30, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.The new test delivers faster...
March 23, 2026 11:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche inaugurates new research home for the Institute of Human Biology, pioneering human model systems to accelerate drug discovery and development

The new building is part of a CHF 1.4 billion site investment, reinforcing Roche’s commitment to Switzerland and the Basel life sciences clusterThe Institute of Human Biology (IHB) enables scientists...